Phase 1 Clinical Trial of Recombinant Interleukin-2: A Comparison of Bolus and Continuous Intravenous Infusion

Abstract The toxicologic, biologic, and clinical effects of recombinant interleukin-2 (IL-2) were tested in 25 patients with cancer. Escalating doses from 103 to 107 U/m2 per day were given by either daily bolus injection (BI) or continuous infusion (CI) for 7 consecutive days. Dose-limiting toxicit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer investigation 1989, Vol.7 (3), p.213-223
Hauptverfasser:	Kohler, Peter C., Hank, Jacquelyn A., Moore, Karen H., Storer, Barry, Bechhofer, Robin, Hong, Richard, Sondel, Paul M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal Antigens, Surface - analysis Antineoplastic Agents - administration & dosage Blood Chemical Analysis Cytotoxicity, Immunologic Dose-Response Relationship, Drug Drug Evaluation Humans Interleukin-2 - administration & dosage Interleukin-2 - adverse effects Interleukin-2 - pharmacokinetics Lymphocytes - immunology Neoplasms - therapy Recombinant Proteins - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!